[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001629:Bezafibrate; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D011345:Fenofibrate / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D000960:Hypolipidemic Agents; D008055:Lipids; D011422:Propionates; D002995:Clofibric Acid; C006012:fenofibric acid; D002994:Clofibrate; D011345:Fenofibrate; D001629:Bezafibrate
Unterschungen zur Wirksamkeit von Bezafibrat und Fenofibrat auf erhöhte Lipide des Blutes bei HLP Typ IIa, IIb, und IV.